# Phase 1 Study of FS-1502 in Patients With HER2 Expressed Advanced Solid Tumors and Breast Cancer.

> **NCT03944499** · PHASE1 · COMPLETED · sponsor: **Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.** · enrollment: 161 (actual)

## Conditions studied

- Solid Tumor
- Breast Cancer

## Interventions

- **DRUG:** FS-1502

## Key facts

- **NCT ID:** NCT03944499
- **Lead sponsor:** Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-11
- **Primary completion:** 2024-05-20
- **Final completion:** 2024-08-12
- **Target enrollment:** 161 (ACTUAL)
- **Last updated:** 2025-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03944499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03944499, "Phase 1 Study of FS-1502 in Patients With HER2 Expressed Advanced Solid Tumors and Breast Cancer.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03944499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*